6 news items
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
CELU
19 Apr 24
modified and unmodified natural killer (NK) cells. Celularity believes that, by harnessing the placenta's unique biology and ready availability, it can
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
CELU
18 Apr 24
-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity believes that, by harnessing the placenta's unique biology and ready
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
CELU
15 Apr 24
stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity believes
Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
CELU
8 Apr 24
its investigational natural killer (NK) cell therapy programs at this year's
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
CELU
8 Apr 24
today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year's
7db7tzf ndt4787iox
CELU
20 Mar 24
-cells, natural killer (NK) cells, mesenchymal stem cells (MSCs), and exosomes." About Celularity
- Prev
- 1
- Next